Synlogic Operating Margin from 2010 to 2024
| SYBX Stock | USD 1.41 0.01 0.71% |
Check Synlogic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Synlogic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 950 or Selling General Administrative of 11.5 M, as well as many indicators such as Price To Sales Ratio of 7.05, Dividend Yield of 0.0 or PTB Ratio of 0.56. Synlogic financial statements analysis is a perfect complement when working with Synlogic Valuation or Volatility modules.
Synlogic | Operating Margin |
Latest Synlogic's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Synlogic over the last few years. It is Synlogic's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Synlogic's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (11.73) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Synlogic Operating Margin Regression Statistics
| Arithmetic Mean | (47.83) | |
| Coefficient Of Variation | (54.39) | |
| Mean Deviation | 20.97 | |
| Median | (59.95) | |
| Standard Deviation | 26.01 | |
| Sample Variance | 676.65 | |
| Range | 94.5834 | |
| R-Value | 0.39 | |
| Mean Square Error | 618.34 | |
| R-Squared | 0.15 | |
| Significance | 0.15 | |
| Slope | 2.26 | |
| Total Sum of Squares | 9,473 |
Synlogic Operating Margin History
About Synlogic Financial Statements
Synlogic investors use historical fundamental indicators, such as Synlogic's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Synlogic. Please read more on our technical analysis and fundamental analysis pages.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease and Ginkgo Bioworks, Inc. Synlogic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Synlogic Stock Analysis
When running Synlogic's price analysis, check to measure Synlogic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synlogic is operating at the current time. Most of Synlogic's value examination focuses on studying past and present price action to predict the probability of Synlogic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synlogic's price. Additionally, you may evaluate how the addition of Synlogic to your portfolios can decrease your overall portfolio volatility.